FDA approves two new indications for Gilead Sciences’ Harvoni to treat chronic hepatitis C
The new indications allow to treat liver transplant recipients with genotype 1 or 4 infection without cirrhosis or with compensated cirrhosis, and for genotype 1-infected patients with decompensated